Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C

Journal of Viral Hepatitis

Volumn 24, Issue 11, 2017, Pages 966-975

  Johnson, K ^a   Green, P K ^b   Ioannou, G N ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ledipasvir; response guided therapy; ribavirin; sofosbuvir

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; ASSAY; COBAS AMPLIPREP ASSAY; COBAS TAQMAN VERSION 2 ASSAY; CONTROLLED STUDY; FEMALE; GOVERNMENT; HEALTH CARE SYSTEM; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REALTIME HCV ASSAY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VIRUS LOAD; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEALTH SURVEY; HEPACIVIRUS; ODDS RATIO; PUBLIC HOSPITAL; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HOSPITALS, VETERANS; HUMANS; ODDS RATIO; POPULATION SURVEILLANCE; RNA, VIRAL; SUSTAINED VIROLOGIC RESPONSE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85023205060     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12731     Document Type: Article

References (30)

1. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-1888.
2. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-1898.
3. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-1493.
4. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, 2016. AASLD and IDSA. http://www.hcvguidelines.org. Accessed January 16, 2017.
5. Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64:405-414.
6. Kowdley KV, Nelson DR, Lalezari JP, et al. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir. Liver Int. 2016;36:1611-1618.
7. Maasoumy B, Vermehren J, Welker MW, et al. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol. 2016;65:473-482.
8. Weingarten S, Agocs L, Tankel N, et al. Reducing lengths of stay for patients hospitalized with chest pain using medical practice guidelines and opinion leaders. Am J Cardiol. 1993;71:259-262.
9. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32-36.
10. Kramer JR, Davila JA, Miller ED, et al. The validity of viral hepatitis and chronic liver disease diagnoses in veterans affairs administrative databases. Aliment Pharmacol Ther. 2008;27:274-282.
11. Kramer JR, Giordano TP, Souchek J, et al. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005;100:56-63.
12. Ioannou GN, Splan MF, Weiss NS, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5:938-945.
13. Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154:85-93.
14. Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57:249-257.
15. Beste LA, Leipertz SL, Green PK, et al. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Gastroenterology. 2015;149;1471-1482:e5.
16. Kramer JR, Kanwal F, Richardson P, et al. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011;106:483-491.
17. Beste LA, Ioannou GN, Larson MS, et al. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol. 2010;8:972-978.
18. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46:37-47.
19. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140:1182-1188e1.
20. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the department of veterans affairs based on computerized patient data. Diabetes Care. 2004;27(Suppl 2):B10-B21.
21. Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61:41-45.
22. Harvoni Package Insert. https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf". Accessed January 26 2016.
23. Inoue T, Hmwe SS, Shimada N, et al. Clinical significance of two real-time PCR assays for chronic hepatitis C patients receiving protease inhibitor-based therapy. PLoS ONE. 2017;12:e0170667.
24. Ogawa E, Furusyo N, Murata M, et al. Comparison of the abbott realtime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy. Antivir Ther. 2017;22:61-70.
25. O'Brien TR, Lang Kuhs KA, Pfeiffer RM. Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis 2014;1:ofu110.
26. Su F, Ioannou GN. Reply to: race or genetic makeup for HCV treatment decisions?. Hepatology. 2017;65:2125-2126.
27. Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Gastroenterology. 2016;151:457-471e5.
28. Su F, Green PK, Berry K, et al. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 2017;65:426-438.
29. Chronic hepatitis C virus (HCV) infection: treatment considerations. From the Department of Veterans Affairs National Hepatitis C Resource Center Program and the National Viral Hepatitis Program in the Office of Patient Care Services. Revised March, 2017: http://www.hepatitis.va.gov/provider/guidelines/hcv-treatment-considerations.asp. Accessed May 1 2017.
30. Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis. 2015;60:1743-1751.